ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Caixin

Eli Lilly partners with Shanghai Junshi for COVID-19 cure

Deal empowers Chinese company to fast-track promising coronavirus therapies

The joint effort may allow the partnership to initiate clinical studies in the U.S. later this year, as the dramatic drop of COVID-19 patients in China makes trials there more difficult.   © Reuters

U.S. pharmaceutical Eli Lilly is partnering with Chinese drugmaker Shanghai Junshi Biosciences to develop new antibody therapies for COVID-19, the disease that has sickened 3.6 million people worldwide.

The companies will collaborate on therapeutic antibody research that could be used to treat and prevent SARS-COV-2, the virus that causes COVID-19, Hong Kong listed Junshi said in a statement. The deal is worth up to $330 million to Junshi.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more